What is "siltuximab"

n. A monoclonal antibody and antineoplastic.

Siltuximab ( INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of metastatic renal cell cancer, prostate cancer, and Castleman's disease, among other types of cancer.

It has undergone a phase I clinical trial in patients With B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease. There were encouraging results in a small trial for advanced ovarian cancer.

Encouraging results have been reported from a phase II trial for relapsed or refractory multiple myeloma.

On April 23, 2014, siltuximab was FDA approved under the brand name of Sylvant for the treatment of patients with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus ( HIV) or human herpesvirus-8 ( HHV-8).